Houston hospital first in U.S. to use new system for minimally invasive surgery

sharper images

Baylor St. Luke's has debuted Allia Moveo, a cutting-edge imaging system for minimally invasive surgeries. Photo courtesy CommonSpirit Health.

Houston’s Baylor St. Luke’s Medical Center has introduced an innovative new surgical imaging system that will allow surgeons to increase the number of minimally invasive procedures as well as reposition on the fly during operations.

Minimally invasive surgery has been shown across the board to improve patient outcomes with less chance of infection and shorter recovery times compared to traditional open surgery. However, the human body is not exactly easy to work on through small incisions, necessitating the development of state-of-the-art cameras and imaging technology to guide surgeons.

Enter GE HealthCare’s Allia Moveo, now a part of the Baylor St. Luke’s Medical Center operating room. Using cutting-edge technology, it uses the same high-definition imaging usually seen in the catheterization lab at speeds fast enough to respond to shifting surgical conditions. Its cable-free setup allows surgeons to switch positions much faster, and it features advanced 3D imaging that compensates for breathing motion and interference from metal implants.

Its design supports a range of cardiovascular, vascular, non-vascular, interventional and surgical procedures, according to CommonSpirit Health, a nonprofit Catholic health network, of which Baylor St. Luke's is a member.

“This innovative platform enhances how our clinicians navigate complex minimally invasive procedures by improving mobility, image clarity, and workflow efficiency. It strengthens our ability to deliver precise, patient-centered care while supporting our teams with technology designed for the evolving demands of modern interventional medicine,” Dr. Brad Lembcke, president of Baylor St. Luke’s Medical Center, said in a news release from Baylor and the Texas Heart Institute.

Baylor St. Luke’s is the first hospital in the U.S. to use the Allia Moveo technology. The definition and responsiveness of the new system allow surgeons to navigate the body with greater accuracy and smaller incisions, even for very delicate operations.

“Allia Moveo gives us the flexibility and image quality needed to manage increasingly complex minimally invasive procedures with greater confidence,” Dr. Gustavo Oderich, vascular surgeon and professor of surgery at Baylor College of Medicine, added in the release. “The ability to quickly reposition the system, obtain high-quality 3D imaging, and integrate advanced guidance tools directly into the workflow enhances procedural accuracy. This technology supports our mission to push the boundaries of what is possible in endovascular and interventional surgery.”

From Your Site Articles
Houston-based Decisio's virtual care technology has been paired with GE Healthcare and Microsoft technology in a new initiative for hospitals dealing with the COVID-19 outbreak. Photo via decisiohealth.com

GE, Microsoft tap Houston startup's technology for virtual COVID-19 treatment initiative

team work

Houston-based health tech startup Decisio Health Inc. has been enlisted in the war against the novel coronavirus.

Chicago-based GE Healthcare Inc. has tapped Decisio's AI-powered DECISIOInsight software, which enables health care providers to remotely monitor patients, for an initiative involving Redmond, Washington-based Microsoft Corp. that's designed to help treat COVID-19 patients.

The coronavirus-targeted Mural Virtual Care Solution, which was introduced April 15, marries Decisio's virtual monitoring software with GE Healthcare's telehealth technology and Microsoft's Azure cloud-computing platform. It's designed to offer hospitals a broad view of COVID-19 patients who are hooked up to ventilators in ICUs. This platform merges data from ventilators, patient monitoring systems, electronic health records, labs, and other sources.

This special technology package is a stripped-down version of the Mural Virtual Care Solution, which pairs Decisio's and GE Healthcare's technology to virtually track hospital patients. GE Healthcare invested in Decisio in 2019.

Until January 31, 2021, the Mural coronavirus bundle is being provided at no cost to hospitals. Among the users is Oregon Health & Science University in Portland.

"We're trying to carry as much of the cost burden to make this as sustainable as possible for our hospital partners that we know are hurting economically right now," says Bryan Haardt, CEO of Decisio.

"There has to be a moralistic compass," he adds. "You have to be driven by something more than just profit."

GE Healthcare, which contributed to Decisio's $13 million Series B round in December, was already partnering with the startup on the Mural Virtual Care Solution. Microsoft was brought into the mix to speed up delivery of the platform in response to the coronavirus pandemic.

"This relationship did not exist prior to this initiative," Haardt says. "We all came together and said, 'Guys, we've got to do our part. It is absolutely a moral imperative that we get together.' And we said, 'OK, well, what are the parts?'"

Haardt says this project equips hospitals to adhere to the best standards of care when it comes to treating COVID-19 patients who are relying on ventilators. In a COVID-19 treatment setting, one of the key benefits of the Mural Virtual Care Solution is that a health care clinician can monitor a patient's vital signs and other data without physical contact, he says.

Founded in 2013, Decisio built its virtual health platform using technology licensed from and developed at the University of Texas Health Science Center in Houston. Coupling real-time clinical surveillance with data visualization, the DECISIOInsight software can pinpoint risks and guide clinicians toward better decisions about patient care.

Haardt says Decisio's software aims to reduce the rate of hospital deaths, length of hospital stays, and burden on hospital resources by helping health care providers decrease the severity of hospital-acquired infections, pneumonia, the flu, and other conditions. Baylor St. Luke's Medical Center in Houston is among the customers for Decisio and GE Healthcare's broad-based Mural Virtual Care Solution, which was rolled out last year.

Also, Decisio has teamed up with professional services firm Deloitte to deliver virtual patient monitoring at U.S. Department of Defense hospitals. This technology is being piloted at Brooke Army Medical Center in San Antonio and Naval Medical Center San Diego.

"We look at doctors and nurses as heroes, because they're really good at getting people out of trouble," Haardt says. "And we like to think of our solution as keeping people out of trouble, because if you can keep them out of the trouble, then these heroic, herculean efforts [by doctors and nurses] are not required as much … ."

Haardt explains that Decisio's technology can monitor patient activity and detect patient trends in not just one area of a hospital (such as an ICU) or throughout an entire hospital but across a commonly managed group of hospitals. Those insights help hospitals ensure all of their health care professionals are following the same treatment protocols.

The No. 1 economic detriment to hospitals "is doing things different at all their different facilities," Haardt says. "If you can reduce the variability of care, we know the cost to provide goods and services goes down, and we know the outcomes improve."

Decisio Health Inc. is designing data-driven resources for clinicians and patients using virtual care. Photo via decisiohealth.com

Houston virtual health care company receives investment from GE for its $13M series B

Money moves

A Houston-based health tech company is wrapping up its series B fundraising round with an investment from Chicago-based GE Healthcare.

The fundraising round is in its initial closing, says Gray Hancock, COO Decisio Health Inc., and is expected to close at $13 million. Decisio has previously raised $7 million, according to Crunchbase. The funds will be used for product development, support, and ongoing growth in operations.

"This investment really cements our partnership with GE Healthcare," Hancock tells InnovationMap in an email. "We signed a global distribution agreement with them earlier this year, so the investment is another step forward in our strategic alignment."

GE Healthcare also invested in Massachusetts-based Formlabs, which makes low-cost 3D printers for anatomical models, and U.K.-based CMR Surgical Ltd., which specializes in surgical robotics.

"Healthcare's next chapter will be written in part by emerging technologies like 3D printing, robotic surgery and virtual patient monitoring," says Kieran Murphy, president and CEO of GE Healthcare, in a news release. "That's why we're putting GE Healthcare's innovative engine and resources behind collaborations with these exciting, next generation companies – to help change the way clinicians work and enable more precise patient care."

Decisio is a virtual care monitoring software that was founded in 2013 based on technology licensed from and developed at the University of Texas Health Science Center in Houston. Using real-time clinical surveillance with data visualization, the DECISIOInsight software can identify risk that helps clinicians make better patient care decisions virtually.

"Our theory was that if you can make the clinicians job's easier, and improve the outcomes for the patients then costs will come down," Hancock says. "But the care of the patient comes first. Do that right and the cost savings will follow. We say its 'where outcomes meet income.'"

In 2015, Decisio Health was approved by the Food and Drug Administration class II medical device, which made it the first FDA-cleared web-native software.

For Decisio, the future of health care is virtual, and the company is determined to design the best technology for clinicians and patients alike.

"Virtual Care is the next step beyond traditional telemedicine, which — for many years — was limited to having a teleconference or even just a phone call with a caregiver," Hancock says. "Now we can start sharing real-time clinical data with clinicians wherever they happen to be located."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings